MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garver, T. D.
Right arrow Articles by Billingsley, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garver, T. D.
Right arrow Articles by Billingsley, M. L.

Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase

TD Garver, GA Oyler, KA Harris, R Polavarapu, Z Damuni, RA Lehman and ML Billingsley

Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey 17033, USA.

Tau is a neuron-specific, microtubule-associated protein that forms paired helical filaments (PHFs) of Alzheimer's disease when aberrantly phosphorylated. We have attempted to elucidate the protein kinases and phosphatases that regulate tau phosphorylation. Incubation of rat, human, and rhesus monkey temporal neocortex slices with the phosphatase inhibitor okadaic acid induced epitopes of tau similar to those found in PHFs. Okadaic acid (1-20 microM) induced variant forms of tau at 60- 68 kDa, which were recognized by the monoclonal antibodies Alz-50 (in humans only) and 5E2 and two polyclonal antipeptide antisera, OK-1 and OK-2. The phosphorylation-sensitive monoclonal antibody Tau-1 failed to recognize the slowest mobility forms of tau after okadaic acid treatment. FK-520 (1-10 microM), a potent inhibitor of calcineurin activity, was tested in brain slices and found not to alter tau mobility. However, combinations of FK-520 (5 microM) and okadaic acid (100 nM) caused tau mobility shifts similar to those seen after 10 microM okadaic acid treatment; similar results were seen using the calcineurin-selective inhibitor cypermethrin. Treatment of human slices with 10 microM okadaic acid decreased both protein phosphatase 2A and calcineurin activity; FK-520 inhibited only protein phosphatase 2B activity. A proposed tau-directed kinase, 42-kDa mitogen-activated protein kinase (p42mapk), was activated by okadaic acid (> 100 nM) but not FK-520 (5 microM). Nerve growth factor (100 ng/ml) activated p42mapk, particularly when used in combination with 100 nM okadaic acid; changes in tau mobility were seen when this kinase was activated. Forskolin (2 microM) antagonized the effects of nerve growth factor on both p42mapk activity and tau phosphorylation; forskolin alone had little effect on PHF-like tau formation induced by phosphatase inhibitors. These results outline complex interactions between tau- directed protein kinases and protein phosphatases and suggest potential sites for therapeutic intervention.

Volume 47, Issue 4, pp. 745-756, 04/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C.-X. Gong, T. Lidsky, J. Wegiel, L. Zuck, I. Grundke-Iqbal, and K. Iqbal
Phosphorylation of Microtubule-associated Protein Tau Is Regulated by Protein Phosphatase 2A in Mammalian Brain. IMPLICATIONS FOR NEUROFIBRILLARY DEGENERATION IN ALZHEIMER'S DISEASE
J. Biol. Chem., February 25, 2000; 275(8): 5535 - 5544.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
T. D. Garver, R. L. Kincaid, R. A. Conn, and M. L. Billingsley
Reduction of Calcineurin Activity in Brain by Antisense Oligonucleotides Leads to Persistent Phosphorylation of tau  Protein at Thr181 and Thr231
Mol. Pharmacol., April 1, 1999; 55(4): 632 - 641.
[Abstract] [Full Text]


Home page
J. Neurosci.Home page
E. Runden, P. O. Seglen, F.-M. Haug, O. P. Ottersen, T. Wieloch, M. Shamloo, and J. H. Laake
Regional Selective Neuronal Degeneration after Protein Phosphatase Inhibition in Hippocampal Slice Cultures: Evidence for a MAP Kinase-Dependent Mechanism
J. Neurosci., September 15, 1998; 18(18): 7296 - 7305.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
Y. Matsuoka, X. Li, and V. Bennett
Adducin Is an In Vivo Substrate for Protein Kinase C: Phosphorylation in the MARCKS-related Domain Inhibits Activity in Promoting Spectrin-Actin Complexes and Occurs in Many Cells, Including Dendritic Spines of Neurons
J. Cell Biol., July 27, 1998; 142(2): 485 - 497.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kins, A. Crameri, D. R. H. Evans, B. A. Hemmings, R. M. Nitsch, and J. Gotz
Reduced Protein Phosphatase 2A Activity Induces Hyperphosphorylation and Altered Compartmentalization of Tau in Transgenic Mice
J. Biol. Chem., October 5, 2001; 276(41): 38193 - 38200.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics